<DOC>
	<DOC>NCT01451580</DOC>
	<brief_summary>To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.</brief_summary>
	<brief_title>Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>histologically proved breast cancer with metastatic disease life expectancy less than 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Phase II</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>